Ask AI
PI3K and AKT Inhibitors for Advanced HR Pos BC

CE / CME

Treatment Selection for the Management of Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer and PIK3CA/AKT1/PTEN Alterations

European Learners: 0.50 EBAC® CE Credit

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: February 13, 2026

Expiration: August 12, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following can help inform the selection of inavolisib with palbociclib and fulvestrant in a patient with hormone receptor–positive (HR+)/HER2-negative (HER2-) locally advanced or metastatic breast cancer that previously received adjuvant therapy?

2.

Your patient with HR+/HER2- advanced recurrent metastatic breast cancer (MBC) and PIK3CA mutation has begun experiencing increasing fasting blood glucose levels on laboratory results after starting treatment with an inavolisib-based regimen. The patient had no known risk factors for diabetes or hyperglycemia at treatment start. Her fasting blood glucose was 115 mg/dL (A1C 4.8%) at baseline and fasting blood glucose is now 155 mg/dL after 3 months of receiving inavolisib-based therapy.

Which of the following prescribing information recommendations would you take into consideration for addressing the rising levels in fasting blood glucose in this patient?